CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Choosing an IRA index fund matters for tax-advantaged growth; compare funds by fees, diversification, and track record to pick confidently.
22,995 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Investors over 50 are recalibrating away from crowded AI bets toward dividend growth and quality stocks that pay risi...
OpenAI accelerates its shift from software to silicon and bio bets, unveiling a custom chip, a DRAM stake, and a majo...
A bipartisan plan to overhaul the USPS centers on drastic steps, including shutting down post office operations in se...
Peek behind the curtain of a renowned star’s private life. This fictional profile of the Neill family reveals how mon...
Two specialty retailers sit on opposite ends of the consumer tech spectrum. By unpacking their revenue trends, invest...
As AI workloads surge, memory becomes a key battleground. This guide breaks down Micron and Sandisk fundamentals, gro...
Apple and Nvidia sit at the pinnacle of market caps, but they play very different roles in investors’ portfolios. Thi...
Two tech names, two very different stories. This guide breaks down Palantir and Microsoft to answer a simple question...
Investors face a pivotal choice in 2026: M/I Homes versus Champion Homes. This guide breaks down how each builder ear...
Two very different tech plays collide in 2026: Innodata edges into AI data preparation, while Workiva anchors large e...
Bitcoin, XRP and Ethereum moved in narrow ranges on Feb. 24, 2026, as traders weigh macro data and liquidity conditio...